Q&A CXO 行业是不是真的又行了？20250710 摘要 创新药企资金来源多元，产品销售增长显著，受益于重磅产品上市和医 保政策宽松，行业整体销售额增长 30%-40%。二级市场融资（IPO 和 增发）同比增长超 60%，港股表现活跃，增发增长超 80%，BD 首付款 也显著增加，复苏迹象明显。 CXO 行业订单在 2025 年第二季度显著改善，6 月尤为突出。临床阶段 人员招聘增加，独立实验排期变化，表明整体需求侧有所改善，预示中 期订单确定性增强。 临床板块订单恢复受两类客户驱动：首付款落地后加大投入的客户，以 及受 BD 项目影响，推动独立实验和临床一期以增加未来 BD 潜力的客 户。临床端改善不仅是短期波动，更是行业整体需求改善和竞争格局变 化的结果。 生产端产能利用率直接影响企业利润。产能利用率偏离 80%水平过多时， 公司需通过低价方式获取订单，导致利润下降。需求好转时，公司无打 价格战动力。观察二三线公司产能利用率可判断整体需求端变化。 近年来 CXO 行业的融资情况如何变化？ 从 2020 年到 2021 年，CXO 行业的一级市场融资保持在约 1,000 亿元人民币 的高水平。然而，20 ...

京新药业 20250710 摘要 金鑫药业创新药地达西尼已上市并纳入医保，2025 年上半年销售额突 破 5,000 万元，预计全年达 1.2-1.3 亿元，市场表现良好，进院数量和 单院产量均符合预期，销量逐月爬升，但综合医院销售节奏稍慢于专科 医院。 口服 RPA 是金鑫药业在血脂异常治疗领域的重要研发成果，目前处于临 床一期试验阶段，已完成部分单剂量和多次给药组试验，预计年内完成 一期试验并启动二期，现有数据显示 LC 降幅良好，与动物实验数据预 期一致。 地达西尼目前已覆盖约 470 家医院，上半年新增 270 多家，目标年底 覆盖 700 家。部分医院月均发货量已达 4,000-5,000 盒以上，整体销 售额逐月增长，从 3 月份约 3 万盒到 6 月份超过 13 万盒，全年目标为 18 万至 20 万盒。 失眠治疗领域在中国沉寂近 20 年，市场需求旺盛。地达西尼临床试验 显示安全性良好，疗效覆盖轻症到重症失眠患者，优于仅适用于轻症患 者的新靶点药物，有望推动整个领域发展。 Q&A 金鑫药业在创新药研发方面的主要方向是什么？ 金鑫药业的创新药研发主要集中在两个大方向：精神神经领域和心脑血管领域。 ...

先达股份 20250710 摘要 公司二季度整体毛利约 3 亿元，洗澡桶贡献超 1 亿元，占比约 30%，异 恶草松、乙草烟等产品亦贡献显著。比多奎早指收入已入账约 50%- 60%，剩余部分 7 月入账。预计第三季度毛利或增加超 1 亿元。 洗澡桶价格 4-6 月波动，大客户价格稳定在 13-14 万元，小客户接近 14 万元。预计四季度旺季结束后价格可能回落，但幅度待定。公司对外 报价未下滑，维持大客户报价 13 万多。 印度无复产计划，一帆即使复产也难赶上旺季订单，对市场价格影响有 限。去年下半年至今，公司通过焚烧炉工艺改进和新焚烧炉投运，成本 控制显著改善，处于行业中上水平。 葵草酮和吡唑葵草酯是水稻田除草剂，吡唑葵草酯市场空间更大，目标 收入五六亿元，预计三到四年内实现。公司正进行试验和海外登记，扩 大国际市场份额。 北美小龙（北北小棕）与跨国公司合作，已签署保密协议，待取得登记 证后签订正式协议。产品正在评审，需补充材料，预计下一次会议可能 上会。2025 年上半年创新药收入贡献约 40~50 万元，毛利 2000 多万 元。 Q&A 2025 年上半年先达股份业绩预增的主要原因是什么？ 2025 ...

研究早观点 2025 年 7 月 11 日 星期五 市场走势 资料来源：最闻 国内市场主要指数 | 指数 | 收盘 | 涨跌幅% | | | --- | --- | --- | --- | | 上证指数 | 3,509.68 | 0.48 | | | 深证成指 | 10,631.13 | 0.47 | | | 沪深 300 | 4,010.02 | 0.47 | | | 中小板指 | 6,634.33 | 0.40 | 格跟踪 | | 创业板指 | 2,189.58 | 0.22 | | | 科创 50 | 979.99 | -0.32 | | 资料来源：最闻 分析师： 李召麒 执业登记编码：S0760521050001 电话：010-83496307 【今日要点】 【行业评论】银行：行业快报：稳定币新纪元，监管政策逐渐完善 【行业评论】通信：山西证券通信行业周跟踪：Coreweave 开启首批部 署 GB300，星网发展有望加速 【行业评论】生物医药Ⅱ：创新药动态更新：PD-1(L1)/VEGF 双抗： 多项 NSCLC III 期临床达到 PFS 终点，结直肠癌等肿瘤一线临床获益 明显 【公司评论】【山证 ...

Core Viewpoint - The company, Morning Bio, is experiencing a significant recovery in its performance, with a projected net profit increase of 102.33% to 132.38% in the first half of 2025 compared to the same period last year, primarily driven by the recovery of its cottonseed business and growth in plant extraction products [1][4]. Group 1: Financial Performance - Morning Bio expects a net profit of 202 million to 232 million yuan in the first half of 2025, compared to 99.83 million yuan in the same period last year [1][4]. - In 2023, the company achieved a record high revenue of 6.872 billion yuan and a net profit of 480 million yuan [3]. - In 2024, the company faced challenges with a net profit drop of 80.39% to 94.05 million yuan due to significant losses in the cottonseed business [3][4]. Group 2: Business Segments - The recovery in the cottonseed business is attributed to improved market conditions, with the company planning to increase the protein content in its products to enhance profitability [4][7]. - The plant extraction business, including products like chili red, chili essence, and stevia glycosides, has shown a year-on-year increase in gross profit, contributing to overall performance improvement [1][4]. Group 3: Industry Position - Morning Bio has become the largest listed company in China's plant extraction industry and ranks among the top tier globally, competing with international leaders [5][6]. - The company has developed proprietary technologies for extracting chili red pigment, positioning China as a leading producer in this sector [5]. Group 4: Technological Advancements - The company has invested nearly 10 million yuan in process improvements for its cottonseed business and over 3 million yuan in upgrading its stevia production line, achieving a 30% reduction in production costs [7]. - The first quarter of 2025 saw the plant extraction business generate 867 million yuan in revenue, a 13.78% increase year-on-year, attributed to a successful volume-based pricing strategy [7].

Group 1 - The core viewpoint of the articles highlights the advancements and innovations in the pharmaceutical and manufacturing sectors in Hanzhong, particularly focusing on Hanjing Pharmaceutical and Guda CNC (Hanzhong) Co., Ltd [1][2][3] - Hanjing Pharmaceutical, established in 1970, specializes in the research, production, and sales of chemical raw materials, intermediates, and pharmaceutical preparations, providing high-quality and affordable medicines to a wide market [1] - The company has developed modern production facilities equipped with self-developed drug reaction furnaces and waste treatment systems, ensuring high purity and compliance with environmental standards [1] - Hanjing Pharmaceutical has established four high-end production workshops and has a significant market presence both domestically and internationally, exporting to over 100 countries and regions [1] Group 2 - Continuous investment in research and development has been a key factor in Hanjing Pharmaceutical's achievements, with the establishment of provincial academician and expert workstations leading to significant scientific advancements [2] - Guda CNC (Hanzhong) Co., Ltd. has rapidly developed its production capabilities, launching a new assembly line for CNC machine tools within three months, with an annual R&D investment of 30 million yuan [2] - The company produces 16 types of high-end intelligent equipment, achieving breakthroughs in core components and control systems, thus enhancing the competitiveness of the domestic manufacturing sector [2][3] - The introduction of advanced CNC technology allows for significant efficiency improvements, with one CNC machine completing the work of four traditional machines in a fraction of the time [3]

Core Points - The article discusses the increasing trend of graduate students in China choosing to withdraw from their programs, highlighting the pressures and challenges they face in academia [1][3][4] - It presents statistics indicating a significant number of students are unable to graduate on time, with one in four graduate students not completing their programs [2][3] - The narrative includes personal stories of students who have withdrawn, illustrating their struggles with academic pressure, mental health, and the expectations placed upon them by family and society [5][6][12] Group 1 - The number of applicants for the national master's degree examination in 2025 is projected to be 3.88 million, with only 872,200 spots available, leading to nearly 3 million students being unsuccessful [2] - Approximately 500,000 students drop out of Chinese universities each year, with a dropout rate of nearly 3% among enrolled students [2] - The pressure faced by graduate students has intensified despite an increase in enrollment opportunities, leading to feelings of burnout and internal conflict [3][4] Group 2 - Students who withdraw often do so after prolonged periods of distress, indicating that the decision is not made lightly but is a culmination of various pressures [5][12] - Personal accounts reveal that students feel trapped in their academic paths, often driven by external expectations rather than personal interests [14][22] - The article emphasizes the emotional toll of academic life, with students experiencing anxiety, insomnia, and a sense of inadequacy [15][49] Group 3 - The transition from undergraduate studies to graduate research is marked by a shift in focus that many students find challenging, leading to feelings of being overwhelmed [18][19] - The article highlights the competitive nature of graduate programs and the lack of support that students often encounter, contributing to their decision to leave [20][27] - The experiences shared by students illustrate a broader issue within the academic system, where the pressure to succeed can lead to mental health struggles and a reevaluation of personal goals [26][49] Group 4 - The withdrawal from graduate programs is framed as a form of liberation for some students, allowing them to pursue paths that align more closely with their personal values and interests [64] - The article discusses the societal stigma surrounding dropping out, contrasting it with the acceptance of pursuing higher education as a norm [63] - Students express a desire to redefine success on their own terms, moving away from traditional academic achievements towards more fulfilling life choices [60][64]

长江商报消息通过收购，上海医药（601607）(601607.SH、02607.HK)盈利能力大幅提升。 7月9日晚间，上海医药公告显示，公司预计2025年上半年实现净利润为44.50亿元，同比将增加15.08亿元，涨幅约 52%。 对此，上海医药解释称，公司完成收购上海和黄药业有限公司(以下简称"和黄药业")10%股权的交割手续，公司合 计持有和黄药业股权比例从50%变更至60%，并将其纳入合并报表范围，公司对其会计核算由合营企业的权益法 核算变更为按子公司核算。根据会计准则规定，上市公司投资收益上涨。 上半年净利预增52% 上海医药是沪港两地上市的大型医药产业集团，是控股股东上实集团旗下大健康产业板块核心企业，主营业务医 药工业、医药商业均居中国领先地位，公司医药工业位列全球制药企业50强。 7月9日晚间，上海医药发布公告称，经财务部门初步测算，公司预计2025年上半年度实现归属于母公司所有者的 净利润为44.50亿元，与上年同期相比，将增加15.08亿元，同比增长约52%。 对于利润增长，上海医药介绍，公司于2025年4月25日完成收购上海和黄药业有限公司(以下简称"和黄药业")10% 股权的交割手续， ...

推进3个半月，华大九天（301269）(301269.SZ)的重组以失败告终。 7月9日晚间，华大九天公告称，公司决定终止重大资产重组。 消息发布之后，7月10日，华大九天股价跌5.27%，报收108.64元/股，总市值589.85亿元，单日蒸发32.8 亿元。 长江商报记者注意到，2025年3月末，华大九天发布重组预案，公司拟以发行股份及支付现金的方式收 购芯和半导体科技(上海)股份有限公司(以下简称"芯和半导体")100%股份并募集配套资金。本次交易是 华大九天在2024年12月易主中国电子集团之后推出的首笔资产重组，作为国内电子设计自动化(EDA)行 业的龙头企业，通过本次重组，华大九天将补齐多款关键核心工具，有助于打造全谱系全流程能力，助 力实现EDA全流程工具系统。 本次交易中，募集配套资金的认购方中国电子集团为华大九天实际控制人，中电金投为中国电子集团控 制的企业，因此本次重组构成关联交易。 值得关注的是，本次交易也是中国电子集团入主华大九天之后，上市公司推出的首单资产重组。 2024年12月，中国电子集团筹划华大九天控制权变更，具体为华大九天第二届董事会成员有4名董事辞 职，中国电子集团提名的5 ...

Core Viewpoint - The Chinese pharmaceutical industry is experiencing positive changes driven by policy optimization and innovation, with a focus on internationalization and high-quality development [2][3]. Group 1: Industry Development - China's pharmaceutical industry has become a global leader in the production of active pharmaceutical ingredients (APIs) and small to medium-sized medical devices, playing an increasingly important role in the global pharmaceutical landscape [1][2]. - The industry is transitioning from exporting intermediates and APIs to a comprehensive export of innovative products, marking a significant shift in the internationalization of Chinese pharmaceuticals [2][3]. Group 2: Policy and Regulatory Environment - Recent reforms in drug and medical device regulation have enhanced the safety and effectiveness of products while stimulating innovation within the industry [4][5]. - The acceleration of drug review and approval processes, along with China's membership in the International Council for Harmonisation (ICH), has created a "fast track" for innovative drugs to enter international markets [2][3]. Group 3: Market Strategies and Internationalization - Companies are encouraged to adopt differentiated and refined market entry strategies by analyzing regional market characteristics, disease profiles, payment capabilities, and competitive landscapes [3][4]. - Successful case studies highlight the importance of collaboration, local production, and building partnerships to penetrate target markets effectively [5]. Group 4: Challenges and Future Directions - Despite the progress, the industry faces various internal and external challenges that require modernization of the regulatory system and governance capabilities to ensure high-quality development [3][5]. - The industry must maintain confidence and focus on enhancing innovation capabilities and quality control to navigate complex international environments and competition [5].